IDO1 and cancer: Recent studies have shown that tumor-targeted delivery of small molecule inhibitors toward the IDO1 could efficiently reverse the tumor immunosuppression and then enhance the therapeutic efficacy of chemotherapy and other cancer treatment modalities by activating the host’s immune system [28–30].